AR029538A1 - Composiciones farmaceuticas de agentes estrogenicos - Google Patents

Composiciones farmaceuticas de agentes estrogenicos

Info

Publication number
AR029538A1
AR029538A1 ARP010103094A ARP010103094A AR029538A1 AR 029538 A1 AR029538 A1 AR 029538A1 AR P010103094 A ARP010103094 A AR P010103094A AR P010103094 A ARP010103094 A AR P010103094A AR 029538 A1 AR029538 A1 AR 029538A1
Authority
AR
Argentina
Prior art keywords
ethers
alkyl
halogenated
esters
pharmaceutical compositions
Prior art date
Application number
ARP010103094A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR029538A1 publication Critical patent/AR029538A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Comprende nuevos sistemas portadores o excipientes farmacéuticos y formulaciones farmacéuticas orales que comprenden como ingrediente activo raloxifeno, amoxifeno, droloxifeno, arzoxifeno, o CP 336156, o análogos de los mismos, o un compuesto de las formulas 1 o 2 donde Z es una porcion seleccionada del grupo 3, 4 o 5 donde R1 está seleccionado de H, OH o ésteres C1-12 de éteres de alquilo de los mismos, benciloxi, o halogeno; o éteres C1-4 halogenados; R2, R3, R4, R5 y R6 son H, OH o ésteres C1-12 o éteres de alquilo de los mismos, halogenos, o éteres C1-4 halogenados, ciano alquilo C1-6 o CF3 con la condicion de que cuando R1 es H R2 no sea OH; Y es la porcion de formula 6; R7 y R8 son alquilo o concatenados conjuntamente forman un anillo que contiene nitrogeno, opcionalmente sustituido o una sal farmacéuticamente aceptable de los mismos; y excipientes elegidos entre rellenadores farmacéuticos, deslizantes, lubricantes, agentes lubricantes y antioxidantes.
ARP010103094A 2000-07-06 2001-06-28 Composiciones farmaceuticas de agentes estrogenicos AR029538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21619200P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
AR029538A1 true AR029538A1 (es) 2003-07-02

Family

ID=22806095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103094A AR029538A1 (es) 2000-07-06 2001-06-28 Composiciones farmaceuticas de agentes estrogenicos

Country Status (26)

Country Link
US (2) US20020031548A1 (es)
EP (1) EP1309327B1 (es)
JP (1) JP2004502733A (es)
KR (2) KR100894027B1 (es)
CN (2) CN101416949A (es)
AR (1) AR029538A1 (es)
AT (1) ATE453391T1 (es)
AU (2) AU2001271741B2 (es)
BR (1) BR0112242A (es)
CA (1) CA2415058A1 (es)
CY (1) CY1109915T1 (es)
DE (1) DE60140945D1 (es)
DK (1) DK1309327T3 (es)
EA (1) EA006386B1 (es)
ES (1) ES2336304T3 (es)
HU (1) HUP0301422A3 (es)
IL (2) IL153647A0 (es)
MX (1) MXPA02012891A (es)
NO (1) NO20030030L (es)
NZ (1) NZ523330A (es)
PL (1) PL204866B1 (es)
PT (1) PT1309327E (es)
SI (1) SI1309327T1 (es)
TW (1) TWI294777B (es)
WO (1) WO2002003987A2 (es)
ZA (1) ZA200301004B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236166B2 (en) * 2001-05-01 2006-12-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
JP2005531613A (ja) * 2002-06-13 2005-10-20 ワイス バゼドキシフェン治療規則
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
TW200526206A (en) * 2004-01-13 2005-08-16 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
EP1732889A1 (en) * 2004-04-07 2006-12-20 Wyeth Crystalline polymorph of bazedoxifene acetate
EP1732890A1 (en) 2004-04-07 2006-12-20 Wyeth Crystalline polymorph of a bazedoxifene acetate
PE20060167A1 (es) * 2004-04-08 2006-04-20 Wyeth Corp Formulaciones de dispersion solida que comprende acetato de bazedoxifeno
AU2005233128A1 (en) 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100358517C (zh) * 2004-09-28 2008-01-02 马晶 一种枸橼酸他莫昔芬口腔崩解片及其制备方法
EP2098223A1 (en) * 2004-11-10 2009-09-09 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form
WO2006052254A2 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CN101151026A (zh) * 2005-03-31 2008-03-26 惠氏公司 O-去甲文拉法辛和巴泽昔芬联合产品及其应用
CN101252921A (zh) * 2005-06-29 2008-08-27 惠氏公司 轭合雌激素类物质和苯卓昔芬的制剂
KR101584674B1 (ko) * 2005-08-24 2016-01-13 와이어쓰 엘엘씨 바제독시펜 아세테이트 제형 및 이의 제조방법
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
TW200836774A (en) 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
US20110065751A1 (en) * 2007-10-16 2011-03-17 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2271320A4 (en) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr PHARMACEUTICAL RALOXIFY FORMULATIONS
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
TW201127386A (en) 2009-10-27 2011-08-16 Wyeth Llc Bazedoxifene formulations with antioxidants
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
UY34847A (es) 2012-06-05 2014-01-31 Takeda Pharmaceutical Preparacion sólida
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
BR112017021120A2 (pt) * 2015-04-02 2018-07-03 Theravance Biopharma R&D Ip, Llc forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide
CA2981661C (en) 2015-04-03 2023-10-03 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
EP3334709A1 (en) 2015-08-12 2018-06-20 Incyte Corporation Salts of an lsd1 inhibitor
WO2018010543A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂
KR101683192B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
KR101683193B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552727A (en) * 1968-09-18 1971-01-05 American Air Filter Co Gas scrubbing apparatus
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (ja) * 1992-08-20 2000-04-04 株式会社東芝 画像補正装置
JPH0674903A (ja) * 1992-08-26 1994-03-18 Sumitomo Metal Ind Ltd 平板状被検出材の微小欠陥検出方法及び装置
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
US5342133A (en) * 1992-12-23 1994-08-30 Hewlett-Packard Company Paper moving system for a printer/plotter
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
DE69616396T2 (de) * 1995-02-28 2002-07-11 Eli Lilly And Co., Indianapolis Benzothiophen-Verbindungen, Zwischenprodukte, Zusammensetzungen und Verfahren
US5919800A (en) 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
PT802183E (pt) * 1996-04-19 2002-03-28 American Home Prod Agentes estrogenicos
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
WO1999019293A1 (en) 1997-10-15 1999-04-22 American Home Products Corporation Novel aryloxy-alkyl-dialkylamines
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法

Also Published As

Publication number Publication date
CN101416949A (zh) 2009-04-29
IL153647A0 (en) 2003-07-06
KR20070110454A (ko) 2007-11-16
ES2336304T3 (es) 2010-04-12
NO20030030L (no) 2003-03-03
EP1309327B1 (en) 2009-12-30
ZA200301004B (en) 2004-05-05
US20020031548A1 (en) 2002-03-14
KR100862174B1 (ko) 2008-10-09
HUP0301422A2 (hu) 2003-09-29
TWI294777B (en) 2008-03-21
JP2004502733A (ja) 2004-01-29
DK1309327T3 (da) 2010-04-26
US7759386B2 (en) 2010-07-20
CN1450895A (zh) 2003-10-22
KR20030023689A (ko) 2003-03-19
AU2001271741B2 (en) 2006-10-19
NO20030030D0 (no) 2003-01-03
EP1309327A2 (en) 2003-05-14
PL204866B1 (pl) 2010-02-26
SI1309327T1 (sl) 2010-03-31
ATE453391T1 (de) 2010-01-15
PT1309327E (pt) 2010-02-23
CA2415058A1 (en) 2002-01-17
EA200300122A1 (ru) 2003-06-26
IL153647A (en) 2011-03-31
US20080269198A1 (en) 2008-10-30
AU7174101A (en) 2002-01-21
MXPA02012891A (es) 2003-10-24
DE60140945D1 (de) 2010-02-11
WO2002003987A3 (en) 2002-07-11
EA006386B1 (ru) 2005-12-29
CY1109915T1 (el) 2014-09-10
WO2002003987A2 (en) 2002-01-17
BR0112242A (pt) 2003-06-24
NZ523330A (en) 2005-07-29
KR100894027B1 (ko) 2009-04-22
HUP0301422A3 (en) 2006-07-28
PL365875A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
AR029538A1 (es) Composiciones farmaceuticas de agentes estrogenicos
PA8495101A1 (es) Derivados de 13-metileritromicina
NO2016005I2 (no) Brivaracetam
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
ME00566B (me) Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač
AU8794291A (en) New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
AR006705A1 (es) Compuestos de 3-[4-(2-fenil-indol-1-ilmetil)-fenil]-acrilamida y 2-fenil-1-[4-(amino-1-il-alqu-1-inil)-bencil]-1h-indol-5-ol, metodo para preparar medicamentos y composiciones farmaceuticas que los contiene
PE20030257A1 (es) Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4
AR031930A1 (es) Antagonistas de mch y su uso en el tratamiento de la obesidad
AR030064A1 (es) Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
WO2002003976A3 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003988A3 (en) Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003986A3 (en) Use of substituted indole compounds for treating breast disorders
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO20014119D0 (no) Medikament inneholdende et sulfopyranosylacylglycerolderivat
AR053560A1 (es) Compuestos antibacterianos de 3,3' dialcoxi-2,2' -dihidroxi -1,1' -bifenilo 5,5' disustituidos y metodos relacionados
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
HRP20070030T3 (en) Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
MX9207427A (es) Nuevos compuestos de ester de butilhidroxitolueno-omega-piridilo y composicion farmaceutica que los contiene.

Legal Events

Date Code Title Description
FC Refusal